J&J beats Q3 estimates, pharma sales $16.76B; plans hip/knee spinoff by 2027

Johnson & Johnson reported quarterly earnings above consensus, with pharmaceutical sales reaching $16.76 billion. The company reiterated plans to spin off its hip and knee division by 2027, a strategic move to focus on higher-growth segments. The beat is modest and the spinoff timeline is unchanged, so the market impact is limited.